BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31231131)

  • 21. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
    Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
    J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma.
    Wael H; Yoshida R; Kudoh S; Hasegawa K; Niimori-Kita K; Ito T
    Lung Cancer; 2014 Aug; 85(2):131-40. PubMed ID: 24888228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
    Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
    Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
    Kim G; Kim M; Nam EJ; Lee JY; Park E
    Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis.
    Fujiwara T; Hiramatsu M; Isagawa T; Ninomiya H; Inamura K; Ishikawa S; Ushijima M; Matsuura M; Jones MH; Shimane M; Nomura H; Ishikawa Y; Aburatani H
    Lung Cancer; 2012 Jan; 75(1):119-25. PubMed ID: 21737174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
    Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
    Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
    Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achaete-scute complex homolog-1 promotes DNA repair in the lung carcinogenesis through matrix metalloproteinase-7 and O(6)-methylguanine-DNA methyltransferase.
    Wang XY; Jensen-Taubman SM; Keefe KM; Yang D; Linnoila RI
    PLoS One; 2012; 7(12):e52832. PubMed ID: 23300791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.
    Bhinge K; Yang L; Terra S; Nasir A; Muppa P; Aubry MC; Yi J; Janaki N; Kovtun IV; Murphy SJ; Halling G; Rahi H; Mansfield A; de Andrade M; Yang P; Vasmatzis G; Peikert T; Kosari F
    Oncotarget; 2017 Apr; 8(16):27155-27165. PubMed ID: 28460442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
    Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
    Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
    Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
    Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PDGF-D/PDGFRβ promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway.
    Zhang H; Sun JD; Yan LJ; Zhao XP
    Biochem Biophys Res Commun; 2016 Sep; 478(2):845-51. PubMed ID: 27507215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
    Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
    Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irradiation Decreases the Neuroendocrine Biomarker Pro-Opiomelanocortin in Small Cell Lung Cancer Cells In Vitro and In Vivo.
    Meredith SL; Bryant JL; Babur M; Riddell PW; Behrouzi R; Williams KJ; White A
    PLoS One; 2016; 11(2):e0148404. PubMed ID: 26848743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer.
    Chen C; Breslin MB; Lan MS
    Cell Signal; 2018 Jun; 46():83-91. PubMed ID: 29501727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.
    Kim JH; Lee SY; Choi JE; Do SK; Lee JH; Hong MJ; Kang HG; Lee WK; Shin KM; Jeong JY; Choi SH; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Thorac Cancer; 2020 Jan; 11(1):19-28. PubMed ID: 31691490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
    Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
    Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung.
    Nasgashio R; Sato Y; Matsumoto T; Kageyama T; Hattori M; Iyoda A; Satoh Y; Ryuge S; Masuda N; Jiang SX; Saegusa M
    Lung Cancer; 2011 Dec; 74(3):405-10. PubMed ID: 21601304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ASCL1 represses a SOX9
    Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
    Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.